|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.99 USD | +3.80% |
|
+12.00% | +6.41% |
| Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
| Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
Haemonetics Corporation revised revenue guidance for the fiscal year 2024. For the year, the company expects GAAP total reported revenue growth to be between 7% to 9%. Total organic revenue growth to be between 8% to 10% against previous guidance of total reported revenue growth to be between 6% to 9%.
Total organic revenue growth to be between 7% to 10%.
| 1st Jan change | Capi. | |
|---|---|---|
| +6.41% | 4.62B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.07% | 26.48B | |
| +2.36% | 26.25B | |
| +12.96% | 24.62B |
HAEMONETICS CORPORATION 
